65 related articles for article (PubMed ID: 19630675)
1. Cardiovascular and other physical effects of acute administration of naltrexone in autistic children.
Herman BH; Asleson GS; Powell A; Borghese IF; Ruckman R; Fitzgerald C
J Child Adolesc Psychopharmacol; 1993; 3(3):157-68. PubMed ID: 19630675
[TBL] [Abstract][Full Text] [Related]
2. Effects of acute administration of naltrexone on cardiovascular function, body temperature, body weight and serum concentrations of liver enzymes in autistic children.
Herman BH; Hammock MK; Arthur-Smith A; Kuehl K; Appelgate K
Dev Pharmacol Ther; 1989; 12(3):118-27. PubMed ID: 2721334
[TBL] [Abstract][Full Text] [Related]
3. Lack of hepatotoxicity with naltrexone treatment.
Sax DS; Kornetsky C; Kim A
J Clin Pharmacol; 1994 Sep; 34(9):898-901. PubMed ID: 7983232
[TBL] [Abstract][Full Text] [Related]
4. NTP Toxicology and Carcinogenesis Studies of Coumarin (CAS No. 91-64-5) in F344/N Rats and B6C3F1 Mice (Gavage Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Sep; 422():1-340. PubMed ID: 12616289
[TBL] [Abstract][Full Text] [Related]
5. Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.
Darwish M; Tempero K; Kirby M; Thompson J
Clin Ther; 2006 May; 28(5):715-24. PubMed ID: 16861093
[TBL] [Abstract][Full Text] [Related]
6. [Opiate hypothesis in infantile autism? Therapeutic trials with naltrexone].
Leboyer M; Bouvard MP; Launay JM; Recasens C; Plumet MH; Waller-Perotte D; Tabuteau F; Bondoux D; Dugas M
Encephale; 1993; 19(2):95-102. PubMed ID: 8275903
[TBL] [Abstract][Full Text] [Related]
7. Naltrexone in autistic children: a double-blind and placebo-controlled study.
Campbell M; Anderson LT; Small AM; Locascio JJ; Lynch NS; Choroco MC
Psychopharmacol Bull; 1990; 26(1):130-5. PubMed ID: 2196621
[TBL] [Abstract][Full Text] [Related]
8. The effects of chronic naltrexone treatment in young autistic children: a double-blind placebo-controlled crossover study.
Willemsen-Swinkels SH; Buitelaar JK; van Engeland H
Biol Psychiatry; 1996 Jun; 39(12):1023-31. PubMed ID: 8780837
[TBL] [Abstract][Full Text] [Related]
9. Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.
Johnson F; Setnik B
Pain Physician; 2011; 14(4):391-406. PubMed ID: 21785483
[TBL] [Abstract][Full Text] [Related]
10. Relative oral bioavailability of morphine and naltrexone derived from crushed morphine sulfate and naltrexone hydrochloride extended-release capsules versus intact product and versus naltrexone solution: a single-dose, randomized-sequence, open-label, three-way crossover trial in healthy volunteers.
Johnson FK; Stark JG; Bieberdorf FA; Stauffer J
Clin Ther; 2010 Jun; 32(6):1149-64. PubMed ID: 20637968
[TBL] [Abstract][Full Text] [Related]
11. Naltrexone in young autistic children: a double-blind, placebo-controlled crossover study.
Kolmen BK; Feldman HM; Handen BL; Janosky JE
J Am Acad Child Adolesc Psychiatry; 1995 Feb; 34(2):223-31. PubMed ID: 7896655
[TBL] [Abstract][Full Text] [Related]
12. Naltrexone and communication skills in young children with autism.
Feldman HM; Kolmen BK; Gonzaga AM
J Am Acad Child Adolesc Psychiatry; 1999 May; 38(5):587-93. PubMed ID: 10230191
[TBL] [Abstract][Full Text] [Related]
13. A clinical trial to determine if corelease of morphine and naltrexone from crushed extended-release capsules induces withdrawal in opioid-dependent patients: a descriptive analysis of six patients.
Setnik B; Roland CL; Goli V; Sommerville K; Webster L
J Opioid Manag; 2013; 9(2):139-50. PubMed ID: 23709323
[TBL] [Abstract][Full Text] [Related]
14. Effects of acute and chronic doses of naltrexone on ethanol self-administration in rhesus monkeys.
Boyle AE; Stewart RB; Macenski MJ; Spiga R; Johnson BA; Meisch RA
Alcohol Clin Exp Res; 1998 Apr; 22(2):359-66. PubMed ID: 9581641
[TBL] [Abstract][Full Text] [Related]
15. NTP technical report on the toxicity studies of Dibutyl Phthalate (CAS No. 84-74-2) Administered in Feed to F344/N Rats and B6C3F1 Mice.
Marsman D
Toxic Rep Ser; 1995 Apr; 30():1-G5. PubMed ID: 12209194
[TBL] [Abstract][Full Text] [Related]
16. Single- and multiple-dose pharmacokinetics of a hydrocodone bitartrate extended-release tablet formulated with abuse-deterrence technology in healthy, naltrexone-blocked volunteers.
Darwish M; Yang R; Tracewell W; Robertson P; Bond M
Clin Ther; 2015 Feb; 37(2):390-401. PubMed ID: 25542074
[TBL] [Abstract][Full Text] [Related]
17. Variable dose naltrexone-induced hypothalamic-pituitary-adrenal stimulation in abstinent alcoholics: a preliminary study.
Farren CK; O'Malley S; Grebski G; Maniar S; Porter M; Kreek MJ
Alcohol Clin Exp Res; 1999 Mar; 23(3):502-8. PubMed ID: 10195825
[TBL] [Abstract][Full Text] [Related]
18. Naltrexone in young autistic children: replication study and learning measures.
Kolmen BK; Feldman HM; Handen BL; Janosky JE
J Am Acad Child Adolesc Psychiatry; 1997 Nov; 36(11):1570-8. PubMed ID: 9394942
[TBL] [Abstract][Full Text] [Related]
19. Relationship between hepatotoxicity and induction of replicative DNA synthesis following single or multiple doses of carbon tetrachloride.
Doolittle DJ; Muller G; Scribner HE
J Toxicol Environ Health; 1987; 22(1):63-78. PubMed ID: 3612836
[TBL] [Abstract][Full Text] [Related]
20. NTP Toxicology and Carcinogenesis Studies of Oxazepam (CAS No. 604-75-1) in Swiss-Webster and B6C3F1 Mice (Feed Studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 1993 Aug; 443():1-321. PubMed ID: 12595920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
